34.46
Schlusskurs vom Vortag:
$36.04
Offen:
$37.07
24-Stunden-Volumen:
1.04M
Relative Volume:
0.65
Marktkapitalisierung:
$1.23B
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
+8.19%
1M Leistung:
-11.64%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
Firmenname
First Tracks Biotherapeutics Inc
Sektor
Branche
Telefon
212-373-3000
Adresse
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TRAX
First Tracks Biotherapeutics Inc
|
34.46 | 1.23B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-09-18 | Eingeleitet | Evercore ISI | Outperform |
| 2026-09-16 | Eingeleitet | Guggenheim | Buy |
| 2026-08-18 | Eingeleitet | Wolfe Research | Outperform |
| 2026-06-08 | Eingeleitet | Wells Fargo | Overweight |
| 2026-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2026-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-04-24 | Eingeleitet | Leerink Partners | Outperform |
| 2026-04-24 | Eingeleitet | Wedbush | Outperform |
| 2026-04-23 | Eingeleitet | JP Morgan | Overweight |
| 2026-04-22 | Eingeleitet | Barclays | Overweight |
| 2026-04-21 | Eingeleitet | UBS | Buy |
Alle ansehen
First Tracks Biotherapeutics Inc Aktie (TRAX) Neueste Nachrichten
First Tracks Biotherapeutics raises $200 million in private placement at $32.75 per share - Minichart
First Tracks Biotherapeutics Secures $200 Million Private Placement at $32.75 Per Share - TradingView
First Tracks Biotherapeutics Targets About $200 Million in Placement - TOKENPOST
First Tracks Biotherapeutics Announces $200 Million Private Placement - GlobeNewswire
First Tracks Biotherapeutics (TRAX) Stock Looks Rich Following Phase 1b Celiac Data - Yahoo Finance
Breaking News about First Tracks Biotherapeutics, Inc.Ordinary Shares (Nasdaq:TRAX) - FinancialContent
Markets & StocksFirst Tracks Biotherapeutics, Inc.Ordinary Shares (Nasdaq:TRAX) Stock Quote - FinancialContent
First Tracks Biotherapeutics Inc (TRAX) Stock Price, Quote, News & History - benzinga.com
John Orwin (TRAX) lifts direct stake to 17,995 shares - Stock Titan
Basic earnings per share (basic EPS) of First Tracks Biotherapeutics Inc – FWB:B43 - TradingView
First Tracks Biotherapeutics Inc Cash Flow – FWB:B43 - TradingView
ETFs Investing in First Tracks Biotherapeutics Inc Stocks - tradingview.com
First Tracks Biotherapeutics at wells fargo healthcare conference: data loom By Investing.com - Investing.com South Africa
First Tracks Biotherapeutics at wells fargo healthcare conference: data loom By Investing.com - Investing.com Canada
First Tracks Biotherapeutics Insider Ware J. Anthony Sells 39,265 Shares at $44.78 Following Option Exercise - Kalkine Media
First Tracks Biotherapeutics Director Sold Shares Worth Over $1.7M - TradingView
First Tracks Biotherapeutics (TRAX) director sells shares after option exercise - Stock Titan
TRAX Reiterates by First Tracks -- Price Target Maintained at $5 - GuruFocus
H.C. Wainwright Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Long term debt to total assets ratio of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Which stocks are gapping on Wednesday? - ChartMill
Million-dollar insider sale at First Tracks (NASDAQ: TRAX) after option exercise - Stock Titan
Cash flow from operating activities of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
EBIT per share of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Revenue per share of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Return on assets % of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Total debt of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
After tax other income/expense of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
First Tracks Biotherapeutics Announces Participation in September Investor Conferences - Yahoo Finance
Non-controlling/minority interest of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Total liabilities of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Taxes of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Diluted shares outstanding of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Total operating expenses of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Diluted earnings per share (diluted EPS) of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - tradingview.com
First Tracks Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:TRAX - TradingView
Total revenue of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - tradingview.com
Dilution adjustment of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Price to cash flow ratio of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
CapEx per share of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Number of shareholders of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Enterprise value to EBITDA forward of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - tradingview.com
Net debt of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Gross profit of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
EBIT of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Net current asset value per share of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Free cash flow of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Total liabilities & shareholders' equities of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Non-operating income (total) of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Enterprise value to EBITDA ratio of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Finanzdaten der First Tracks Biotherapeutics Inc-Aktie (TRAX)
Es liegen keine Finanzdaten für First Tracks Biotherapeutics Inc (TRAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
First Tracks Biotherapeutics Inc-Aktie (TRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ware J. Anthony | Director |
Sep 02 '26 |
Option Exercise |
5.74 |
39,265 |
225,381 |
54,925 |
| Ware J. Anthony | Director |
Sep 02 '26 |
Sale |
44.78 |
39,265 |
1,758,145 |
15,660 |
| JOE ANTHONY WARE | Director |
Sep 02 '26 |
Proposed Sale |
44.78 |
39,265 |
1,758,145 |
0 |
| Ware J. Anthony | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
15,660 |
| Jain Rita | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
7,330 |
0 |
19,194 |
| FENTON DENNIS M | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
10,995 |
| Marquet Magda | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
15,960 |
| Schmid John P. | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
37,652 |
| Orwin John A | Director |
Jun 15 '26 |
Option Exercise |
0.00 |
6,030 |
0 |
16,695 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):